

**AMENDMENTS TO THE CLAIMS**

1-2. (cancelled)

3. (currently amended) An isolated antibody that selectively binds to a polypeptide of claim 2, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2.

4-11. (canceled)

12. (currently amended) A method for detecting ~~the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide,~~ a polypeptide having an amino acid sequence consisting of SEQ ID NO:2 in a sample, the method comprising:

(a) contacting the sample with an agent that selectively binds to the polypeptide; and

(b) detecting the binding of the agent to the polypeptide to thereby detect the polypeptide.

13-23. (canceled)

24. (new) A method for detecting a polypeptide having an amino acid sequence comprising SEQ ID NO:2 in a sample, the method comprising:

(a) contacting the sample with an agent that selectively binds to the polypeptide; and

(b) detecting the binding of the agent to the polypeptide to thereby detect the polypeptide.

25. (new) The method of claim 12, wherein the agent is an antibody.

26. (new) The method of claim 24, wherein the agent is an antibody.
27. (new) The method of claim 12, wherein the agent is coupled to a detectable substance.
28. (new) The method of claim 24, wherein the agent is coupled to a detectable substance.
29. (new) The method of claim 25, wherein the antibody is coupled to a detectable substance.
30. (new) The method of claim 26, wherein the antibody is coupled to a detectable substance.
31. (new) An isolated antibody that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2.
32. (new) The antibody of claim 3, wherein the antibody is a monoclonal antibody.
33. (new) The antibody of claim 31, wherein the antibody is a monoclonal antibody.
34. (new) The antibody of claim 3, wherein the antibody is coupled to a detectable substance.
35. (new) The antibody of claim 31, wherein the antibody is coupled to a detectable substance.
36. (new) The antibody of claim 32, wherein the antibody is coupled to a detectable substance.

37. (new) The antibody of claim 33, wherein the antibody is coupled to a detectable substance.
38. (new) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.
39. (new) A composition comprising the antibody of claim 31 and a pharmaceutically acceptable carrier.
40. (new) A composition comprising the antibody of claim 32 and a pharmaceutically acceptable carrier.
41. (new) A composition comprising the antibody of claim 33 and a pharmaceutically acceptable carrier.
42. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide consists of SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
  - b) an F(ab')<sub>2</sub> fragment; and
  - c) an Fv fragment.
43. (new) An isolated antibody fragment that selectively binds to a polypeptide, wherein the amino acid sequence of said polypeptide comprises SEQ ID NO:2, and wherein the antibody fragment comprises a fragment selected from the group consisting of:
- a) an Fab fragment;
  - b) an F(ab')<sub>2</sub> fragment; and
  - c) an Fv fragment.